The DOI matches its Crossref record.
A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group
Open accessAbstract
The efficacy and tolerability of salmeterol, 50 micrograms b.i.d. was compared for three months with salbutamol, 200 micrograms q.i.d., administered from metered-dose inhaler. For the following nine months, safety and clinic lung function was monitored on salmeterol, 50 micrograms b.i.d., compared with salbutamol, 200 micrograms b.i.d. This comparison was made in a multicentre, double-blind, parallel-group study of 667 moderate asthmatics, who had a forced expiratory volume in one second (FEV1) or peak expiratory flow rate (PEFR) > 50% predicted, a 15% reversibility to inhaled salbutamol and who were experiencing symptoms. Throughout the first three month treatment period, both morning and evening PEFR were significantly higher on treatment with salmeterol than salbutamol (mean differences between the treatments 30 l.min-1 for morning, p < 0.001, and 11 l.min-1 for evening, p < 0.01). In addition, the diurnal variation in PEFR, nocturnal and daytime symptoms and use of additional salbutamol were significantly lower in the salmeterol treated group. This improvement was also apparent in the separate subpopulations of patients taking no concurrent glucocorticosteroid or concurrent inhaled and/or oral glucocorticosteroids. Both treatments were well-tolerated throughout the 12 months of treatment. There was a lower incidence of asthma and related events during salmeterol treatment compared to salbutamol treatment subgroups. The results of the study clearly demonstrate that salmeterol, 50 micrograms b.i.d., is well-tolerated and more effective than salbutamol, 200 micrograms q.i.d., in the treatment of moderate asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Asthma: From Bronchoconstriction to Airways Inflammation and Remodeling
BOUSQUET, J., JEFFERY, P. K., BUSSE, W. W., JOHNSON, M., & VIGNOLA, A. M. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.5.9903102 · Cited by 1,702
Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
Pauwels, R. A., Löfdahl, C.-G., Postma, D. S., Tattersfield, A. E., O'Byrne, P., Barnes, P. J., & Ullman, A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711133372001 · Cited by 1,520
Greening, A. P., Ind, P. W., Northfield, M., & Shaw, G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92996-3 · Cited by 972
Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
(1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380222 · Cited by 864
Woolcock, A., Lundback, B., Ringdal, N., & Jacques, L. A. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630590 · Cited by 701
Metadata
- Authors
- Britton, M., Earnshaw, J., & Palmer, J.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 1992-10-01
- Volume
- 5
- Issue
- 9
- Pages
- 1062-1067
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W1572030781
- Cited by
- 181
- References
- 0
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. https://app.cochat.ai/papers/10.1183/09031936.93.05091062
- The paper
- Britton, M., Earnshaw, J., & Palmer, J. (1992). A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. European Respiratory Journal. https://doi.org/10.1183/09031936.93.05091062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.